GenVec gets $430,000 grant to develop vaccine technology

By Elaine Rigoli

Tampa, Fla., Aug. 29 - GenVec, Inc. has received a $430,000 phase 1 small business innovation research award from the National Institute of Allergy and Infectious Diseases Biodefense Program to support the company's efforts to develop novel adenovector-based vaccine technology.

The company will use the funding to research and advance its adenovector technology in order to develop a range of vaccines based on novel serotypes of the adenovirus.

The new vectors produced under the grant will incorporate influenza genes to assess their improved immunogenicity, the company noted.

GenVec is a biopharmaceutical company based in Gaithersburg. Md.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.